Upon March the 6th, 98067 cases of COVID-19 have been diagnosed worldwide. As a company focused on the development of innovative antibody drugs, Sanyou Biopharmaceuticals has obtained anti-virus monoclonal antibodies with neutralizing activity within just 16 days after the outburst, and has stocked a full range of high-quality 2019-nCoV-related proteins and mAbs with rigorous quality control and activity verification. In order to assist more researchers with their research of mechanism, development of diagnostic reagents, development of therapeutic drugs etc., a large number of antibodies are offered for free trial and related products now accept orders or pre-orders.
In order to assist more researchers with their mechanism research, development of diagnostic reagents, development of therapeutic drugs etc., related products now accept orders or pre-orders.
In the past month, we have provided 2019-nCoV protein and antibody products and services to more than 100 institutions or bio-technological companies in China.
The 2019-nCoV S1 protein was expressed using the HEK293 expression system with more the 95% purity.
Fig.1 SDS-PAGE of 2019-nCoV S1 protein L1 is S1-Fc protein, L2 is S1-His protein
Fig. 4 FACS binding test of 2019-nCoV S1 to ACE2 expressing Vero E6 cells
In order to verify the application potential of our antigen and antibody products as raw materials for immunodiagnosis, we used the 2019-nCoV S1 protein as a raw material to make a prototype of the IgG detection kit. The results show that the colloidal gold detection kit has successfully detected the anti-neo coronavirus IgG antibody in the positive quality control, and the sensitivity can reach 10ng.
Fig. 5 Colloidal Gold Test. The first row is the experimental group and the second row is the blank control group, IgG concentration decreases from left to right.
2019-nCoV S1 protein shows excellent affinity to Vero E6 cell surface ACE2.
Fig.7 FACS binding test of 2019-nCoV S1 to ACE2 expressing Vero E6 cells.
Fig. 10 FACS binding test of Anti-Spike-RBD mAb and Spike-RBD protein to ACE2 expressing Vero E6 cells
Fig. 11 Double antibody sandwich Elisa. It shows the pre-bound S1 protein and A1 mAb, pre-bound S1 protein and A2 mAb added A3 monoclonal antibody detection.
Fig. 12 SDS-PAGE of Anti-Spike-RBD single domain mAb
Fig. 14 SDS-PAGE of ACE2proteins L1,L2 are human ACE2 proteins，L3,L4 are murine proteins
Human ACE2 protein has good affinity to 2019-nCoV S1 protein and anti-ACE2 antibody.
Fig.17 SDS-PAGE of Anti-ACE2 human mAb
The Anti-ACE2 human mAb has excellent affinity to ACE2 protein.
Anti-ACE2 mAb blocks the binding of ACE2 protein expressing Vero E6 cells.
Fig.20 ELISA binding of Anti-N-protein mAb and N protein